Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
QAW039 (fevipiprant) add-on therapy in uncontrolled asthma
2017-001273-16Phase 3Completed
- Sponsor
- Novartis
- Start
- Aug 2017
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 3, randomised, double-blind trial in asthma comparing Fevipiprant 150 mg once daily + standard-of-care with Placebo + standard-of-care (2 arms). Primary endpoint: Pre-dose Forced Expiratory Volume in 1 second (FEV1). Started Aug 2017; status: completed.
02
Drugs
fevipiprant
03
Conditions
asthma
Beyond the preview
Go deeper on 2017-001273-16.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on 2017-001273-16.